基于影像引导穿刺与多参数MRI监测的前列腺癌主动监测方案:进展与治疗转化率
该前瞻性研究评估了纳入mpMRI引导基线穿刺和年度mpMRI监测的主动监测方案对 favourable-risk 前列腺癌患者的早期结局。157例患者中位随访39个月,15.9%出现疾病进展,11.7%转为治疗(每年<4%)。仅用PSA和mpMRI变化检测进展的敏感性为70.0%、特异性为81.7%,但按方案再穿刺仍检出6例无PSA或mpMRI变化的病理进展。
要点
- 该方案下疾病进展率15.9%,治疗转化率11.7%,每年转化率<4%。
- mpMRI变化是检测进展的主要触发因素,但按方案再穿刺可检出无影像/PSA变化的病理进展。
- 仅用PSA和mpMRI变化检测进展的敏感性70.0%、特异性81.7%。
核心结论
- 采用全面基线评估和影像学监测的主动监测方案,进展率和治疗转化率均较低。
- mpMRI变化是影像学或病理学检测进展的主要触发因素,但按方案再穿刺仍能检出相当数量无mpMRI或PSA变化的病理进展。
研究设计与样本
- 前瞻性研究,纳入157例 favourable-risk 前列腺癌患者,中位年龄64岁,中位PSA 6.8 ng/mL,中位随访39个月。
- 方案要求影像引导基线穿刺、每年mpMRI和每3个月PSA检测,同时保留按方案再穿刺。
主要发现
- 12例(7.6%)主动退出主动监测方案,剩余145例中104例接受了再穿刺(由PSA升高、mpMRI变化或按方案触发)。
- 23例(15.9%)出现疾病进展,其中20例为病理进展、3例为影像学进展;这23例中17例转为治疗,转化率11.7%(每年<4%)。
- 20例病理进展中,4例由PSA升高触发再穿刺后检出,10例由mpMRI变化后检出,6例仅在按方案再穿刺后检出(无先前PSA或mpMRI变化)。
- 仅用PSA和mpMRI变化检测进展的敏感性为70.0%,特异性为81.7%。
临床怎么用
- 对于 favourable-risk 前列腺癌患者,采用包含影像引导基线穿刺和mpMRI监测的主动监测方案可行,进展和治疗转化率较低。
- 临床中不应仅依赖PSA和mpMRI变化判断进展,按方案再穿刺仍可检出无影像或PSA变化的病理进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess early outcomes since the introduction of an active surveillance (AS) protocol incorporating multiparametric magnetic resonance imaging (mpMRI)-guided baseline biopsies and image-based surveillance. PATIENTS AND METHODS: A new AS protocol mandating image-guided baseline biopsies, annual mpMRI and 3-monthly prostate-specific antigen (PSA) testing, but which retained protocol re-biopsies, was tested. Pathological progression, treatment conversion and triggers for non-protocol biopsy were recorded prospectively. RESULTS: Data from 157 men enrolled in the AS protocol (median age 64 years, PSA 6.8 ng/mL, follow-up 39 months) were interrogated. A total of 12 men (7.6%) left the AS programme by choice. Of the 145 men who remained, 104 had re-biopsies either triggered by a rise in PSA level, change in mpMRI findings or by protocol. Overall, 23 men (15.9%) experienced disease progression; pathological changes were observed in 20 men and changes in imaging results were observed in three men. Of these 23 men, 17 switched to treatment, giving a conversion rate of 11.7% (<4% per year). Of the 20 men with pathological progression, this was detected in four of them after a PSA increase triggered a re-biopsy, while in 10 men progression was detected after an mpMRI change. Progression was detected in six men, however, solely after a protocol re-biopsy without prior PSA or mpMRI changes. Using PSA and mpMRI changes alone to detect progression was found to have a sensitivity and specificity of 70.0% and 81.7%, respectively. CONCLUSION: Our AS protocol, with thorough baseline assessment and imaging-based surveillance, showed low rates of progression and treatment conversion. Changes in mpMRI findings were the principle trigger for detecting progression by imaging alone or pathologically; however, per protocol re-biopsy still detected a significant number of pathological progressions without mpMRI or PSA changes.
引用
- Thurtle D, Barrett T, Thankappan-Nair V, et al. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int. 2018. PMID: 29438586. doi:10.1111/bju.14166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。